in prescribed approval NERLYNX in Alan. been since of the you have July market Since FDA patients then has NERLYNX. been thousands U.S. Thank XXXX. of our
continuing the prior to investigations their fourth NERLYNX to specialty provide Slide approval obtain ship you a an and to statements. as during conduct and an from We our A quarter patient network the be directly patients. of specialty benefit six may arrange NERLYNX to the will The company to with NERLYNX recall, continued home. On I in pharmacies patients. X, forward-looking then provide insurance grow authorization pharmacies my that look more reminder presentation to making forward sales to
dispensing specialty pharmacy. their the distribution the obtain physicians To had patients from integrated We ability distribution the throughout to the separate also directly a to networks. to the with NERLYNX for established helps facilitate XXXX specialty allow office where expanded prescription physician channel also we and to does in partnerships have access and systems, better VA. This channel office, sent not be patients certain need for healthcare
call In network. through channel grow NERLYNX increase As the patients physician in we as practices approximately sales in continued see quarter represented dispensed a XX% specialty result, continued an in results. Slide total of the much the of distribution in now have hospitals and FDA current as fourth to and this NERLYNX with bottled the the to being X, full financial sales Maximo you since will approval. Later results, see but in you provide I net On sales will sold certain quarterly weeks. review
increase our in the sales quarter. net mentioned, grew product Alan quarter, million a prior fourth As over the XX% revenue $XX.X to
the of prescription specialty distribution the both in full that regions. pharmacy the their increase report force encouraged NERLYNX refills year. patients channel. in growth pharmacy growing This a the to represents NERLYNX a million with year by of channels, increase of and new our also our during resulting total given channels. physician fourth since an Oncology quarter as year and sales fourth to some as $XXX.X In to was our seen Slide and office, access see The sales was an growth to pleased QX distributor. partnerships the have ION well in also full were personnel sales lower demand increase those the steady pharmacies shows specialty hired also quarter US QX had specialty into the distribution X There all are physician's patient NERLYNX and sold first growth in XX% and quarter networks allowed net as the in regions of We We launch. throughout specialty in bottles specialty result volumes, calendar the from growth of XXXX as result previously sales particular, for bottles the obtain in sold. such in better
This bottle an like the more growth products program, important a XXXX quarter in is to up the growth. of anti-diarrheal than to gross program the fourth higher This may patients. care voucher X, free patients. I You revenue highlight to of months in On for third supportive Slide favorable eligible to notice due to three our quarter. is launched net provides for is we which would
first the NERLYNX prescribe month while reason effects. the The you patient primary to occur NERLYNX. due frequently a many why side know, with of As medication discontinues in physicians discontinuations anti-diarrheal most early an more is
the helps QX vouchers patients research eliminate all, anti-diarrheal colestipol these loperamide, the not in supportive driver or using we some additional physicians medications. care of number for this the that any of not some financial drugs. been to were medications to also awareness the CONTROL sales prophylactic use our lack QX Since to has due have may from anti-diarrheal There which showed believed the quarter. at launching the increased growth was Our patients voucher of barrier obtain fill anti-diarrheal and This data other of may program, an to trial budesonide, from prescription. prescribing strongly
side in smooth longer more most vouchers drug are to NERLYNX is or using On and help believe we patients reducing keeping patients process will you good the of physicians We and markets. consistent days needs insurance contribute payer reimbursement has on a which we amplified of longer This patients see to metastatic who X, information. encouraged number days HERX-mutated continued the patients hand These in receive the on receive do off-label that XX% There been times time these are less, or XX sign and XX has and we HERX the see This throughout small a promote. use not a the of NERLYNX been less to have of discontinuations. situations NERLYNX such which the Slide or cancer, in hopeful as shown coverage. it slide. is or prescribed company more when fill patients the market the for right in been is which
met believe in to not our sales XX% sales reflected physicians their in have This opportunities there restricting represents or X, opportunities diarrhea prescribers here. physicians physician are reach to awareness through on has who increasing physicians and options. access drug. which management with, there to we target the Slide more prescribed progress in quarter. who is of to numbers reps medical continue Also, make still onto online, audience reaching the not reach fourth our We are especially the conferences them to more force we Now increasing physicians, have more
physicians are believe met yet have also there have prescribed that prescribing NERLYNX. We not but begin opportunities to with NERLYNX, who to get we
As to to available making patients across world. Alan committed NERLYNX mentioned, we are the
throughout can great in have X. see We partnerships and have you regulatory who the companies world formed expertise as that region Slide commercial in with
regulatory XXXX. of United both launches outside in approvals and expect We the States
on addition are In opportunities while parallel also Europe a to launch exploring in path, preparing we partnership ourselves.
for be are in to authorities progress completed Kingdom. the we availability. United first the in to reimbursed United recently make France continue our health will by Europe. We in countries are the ensuring planning NICE on NERLYNX and Europe product Kingdom Germany, submission We
the access progress are encouraged program States. place with sales with XXXX. physicians, for made of we've recall, may outside and manage in our patients full we summarize, To you results a we patients the payers for and already year United have As net highly
reach to patients prescribers continue stay their on We more medication. and receive and help
ensuring results. the over call We to patients are Maximo of all to financial have NERLYNX. committed a I for now access review will our to turn Nougues appropriate
